ACHL: רווח נקי למניה (EPS TTM) Achilles Therapeutics PLC

לוגו של חברה ציבורית Achilles Therapeutics PLC (ACHL)

Achilles Therapeutics (ACHL) is implementing personalized T-cell protection against aggressive tumors. The current earnings per share over the last 12 months illustrates the strategy's effectiveness, with the latest value recorded as -1.66. However, geopolitics remains vulnerable to supply chain sanctions, and the project's commercial success depends on strict FDA approval and patent protection.

ACHL (Achilles Therapeutics) היסטוריית רווח נקי למניה אחת בשנים עשר החודשים האחרונים מ-04.07.2022 עד 29.03.2025

achillestx.com - פילוחים אנליטיים ומדדי מפתח (ACHL)

ניתוח כללי של החברה:Achilles Therapeutics PLC (ACHL)
מוצר סדרתי של Achilles Therapeutics

The diversification of Achilles Therapeutics (ACHL) clinical programs for treating solid tumors allows for the effective distribution of long-term R&D risks. This strategy directly impacts eps_ttm_co, which measures the final trailing twelve-month earnings per share. This metric strips the financial result of the impact of share issuance, revealing the actual efficiency of the business. Investors use it to assess the systemic stability of capital. By analyzing the 12-month net income per share trend, one can determine the true profitability trajectory.

ניתוח חברות מתחרות